Evotec

DGAP-News: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation

Retrieved on: 
Tuesday, May 10, 2022

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018.
  • Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for an additional 8 years with the goal to further broaden and deepen the strategic alliance.
  • Bristol Myers Squibb is a leader in this field based in particular on its unique library of cereblon E3 ligase modulators (CELMoD).
  • We are extremely excited about the opportunity to significantly extend and expand our strategic partnership with Bristol Myers Squibb into 2030 and possibly beyond.

DGAP-News: Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs

Retrieved on: 
Tuesday, May 3, 2022

Paris, France and Munich, Germany, May 3, 2022 - Andera Partners, a leading European private equity player, through its biotech and medtech practice Andera Life Sciences, announced today that it is leading a 60 million (USD $63 million) Series B financing round for Tubulis with participation from new investors Evotec and Fund+.

Key Points: 
  • Paris, France and Munich, Germany, May 3, 2022 - Andera Partners, a leading European private equity player, through its biotech and medtech practice Andera Life Sciences, announced today that it is leading a 60 million (USD $63 million) Series B financing round for Tubulis with participation from new investors Evotec and Fund+.
  • Baker McKenzie (Julia Braun) served as counsel for new Series B investors and CMS (Stefan-Ulrich Mller) for Tubulis.
  • Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally.
  • Its teams manage over 3.2 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Retrieved on: 
Tuesday, May 3, 2022

Tubulis today announced the successful completion of a 60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+.

Key Points: 
  • Tubulis today announced the successful completion of a 60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+.
  • With its unique toolkit of proprietary technologies and its pipeline of differentiated ADC candidates, Tubulis holds a compelling position in the ADC field, stated Andera Partners Sofia Ioannidou, PhD.
  • Tubulis capability of creating a pipeline of antibody-drug conjugates is based on a diverse range of targeting molecules, novel payloads and proprietary conjugation technologies.
  • Baker McKenzie (Julia Braun) served as counsel for new Series B investors and CMS (Stefan-Ulrich Mller) for Tubulis.

DGAP-News: Secarna Pharmaceuticals' strategic partner Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb

Retrieved on: 
Wednesday, April 13, 2022

Evotec is eligible to receive tiered royalties of up to low double-digit percentages of sales of any commercial products resulting from the collaboration with Bristol Myers Squibb.

Key Points: 
  • Evotec is eligible to receive tiered royalties of up to low double-digit percentages of sales of any commercial products resulting from the collaboration with Bristol Myers Squibb.
  • Additionally, Evotec can earn up to US$ 250 m in development and sales milestones within the collaboration.
  • "Congratulations to our partners at Evotec for reaching programme designation within its neuroscience collaboration with Bristol Myers Squibb", said Alexander Gebauer, M.D., Ph.D., CEO of Secarna Pharmaceuticals.
  • The neuroscience collaboration between Evotec and Bristol Myers Squibb aims to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures

Retrieved on: 
Tuesday, April 12, 2022

"Partnered" are funded projects and are mainly run at the ID Lyon site, which was acquired in 2018.

Key Points: 
  • "Partnered" are funded projects and are mainly run at the ID Lyon site, which was acquired in 2018.
  • With the liquidity increase following Evotec's own public offering on NASDAQ, the net debt ratio at 31 December 2021 (excl.
  • In October of 2021, Exscientia Ltd., in which Evotec has a significant stake, successfully completed an IPO on NASDAQ.
  • Revenues, Unpartnered R&D expenses, and adjusted EBITDA remain the financial key performance indicators of the Evotec Group.

DGAP-News: Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb

Retrieved on: 
Tuesday, April 12, 2022

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, NASDAQ: EVO) announced today that the Company has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a payment of US$ 16 m to Evotec.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, NASDAQ: EVO) announced today that the Company has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a payment of US$ 16 m to Evotec.
  • Evotec is eligible to receive tiered royalties of up to low double-digit percentages of sales of any commercial products resulting from the collaboration with Bristol Myers Squibb.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "Our neuroscience collaboration with Bristol Myers Squibb was initiated in December 2016.
  • The neuroscience collaboration between Evotec and Bristol Myers Squibb aims to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

DGAP-News: Evotec SE to announce results for fiscal year 2021 on 12 April 2022

Retrieved on: 
Tuesday, April 5, 2022

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2021 on Tuesday, 12 April 2022.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2021 on Tuesday, 12 April 2022.
  • The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.
  • The on-demand version of the webcast will be available on our website: https://www.evotec.com/financial-reports .
  • Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g.

Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022

Retrieved on: 
Wednesday, March 30, 2022

MIAMI BEACH, Fla., March 30, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, is pleased to provide a business update and summary of key accomplishments since its Initial Public Offering (“IPO”) in September 2021.

Key Points: 
  • Pasithea was founded to improve treatment options for those affected by psychiatric and neurological disorders.
  • This is expected to be a transformational year for Pasithea and I look forward to continued growth and executing on our business strategy in 2022 and beyond, said Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
  • Key Financial and Business Highlights:
    Well capitalized with year-end 2021 cash position of $52.9 million.
  • Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.

TYME Technologies, Inc. Announces Exploration of Strategic Options

Retrieved on: 
Tuesday, March 29, 2022

BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.

Key Points: 
  • BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.
  • Notwithstanding the discontinuation of its most advanced clinical trial, the Company believes there are additional opportunities that could enhance value for TYME stockholders.
  • TYME believes that being well-capitalized affords it the ability to consider a wide range of strategic options and therefore has commenced a formal process with Moelis & Company LLC.
  • The goal of the strategic evaluation process is to ensure that we are exploring a range of possible options to maximize value for our stockholders.

DGAP-News: Evotec receives € 3 m milestone payment for Bayer starting Phase II clinical development of DNP programme

Retrieved on: 
Monday, March 21, 2022

DNP is a common chronic condition associated with nerve damage caused by high blood sugar levels in diabetic patients.

Key Points: 
  • DNP is a common chronic condition associated with nerve damage caused by high blood sugar levels in diabetic patients.
  • DNP may be triggered through the slightest touch upon which the body sends unprompted pain signals to the brain.
  • Bayer has initiated a Phase II clinical trial to evaluate the safety and efficacy of BAY 2395840 in patients with DNP compared to placebo.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited that Bayer is moving ahead with the Phase II clinical development of an asset from our multi-target research alliance.